Navigation Links
PreMD Inc. Provides Corporate Update
Date:10/3/2007

TORONTO, Oct. 3 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) is pleased to announce an update on the company's 510(k) application to the US Food and Drug Administration (FDA) and involvement in upcoming conferences.

On Wednesday, October 3, 2007, Dr. Brent Norton, president and chief executive officer of PreMD, will present at BioContact Quebec, a leading annual biopharmaceutical conference. The conference takes place from October 3-5, 2007, in Quebec City.

PreMD is preparing the information recently requested by the FDA. In September, PreMD held discussions with the FDA in order to clarify the necessary information required to obtain an expanded regulatory claim for the company's POC skin cholesterol test. At this time, pursuant to multiple communications with the FDA and its marketing partner, PreMD anticipates submitting the final response in the coming weeks, within the required timeframe.

PreMD is also involved in several upcoming conferences to be held in Q4 2007. The company will be presenting and exhibiting at the ValueRich Small-Cap Financial Expo on October 18, 2007, in New York. PreMD will also be exhibiting at the Association of Home Underwriters (AHOU) 2007 Annual Conference in Toronto from October 21-24, 2007, on its PREVU(x) LT product. On November 5-7, 2007, PreMD will be presenting at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference in New York.

PreMD is also pleased to announce the presentation date of the scientific abstract entitled 'Increased Skin Cholesterol Identifies Individuals at Increased Cardiovascular Risk: The Predictor of Advanced Subclinical Atherosclerosis (PASA) Study' at the American Heart Association Conference. The AHA Scientific Sessions conference takes place November 2-7, 2007 in Orlando, Florida and the PASA presentation will take place in the morning session on Monday, November 5, 2007.

About PreMD

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products, currently branded as PREVU(x) Skin Cholesterol Test, will be marketed and distributed by AstraZeneca. The company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PREVU(x), please visit http://www.prevu.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the company's products, the competitiveness of the company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions.

In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

(x) Trademark


'/>"/>
SOURCE PreMD Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Protein provides antioxidant protection to Neurons
2. Acupuncture provides relief
3. Micro-camera provides new breast imaging technique
4. Hormone therapy provides no heart benefit
5. MicroRNA provides new insight into birth defects
6. Drug Spironolactone Provides Renal And Cardioprotection In Diabetic Patients
7. Neurobiology Provides Answers To Block Memory-Related Drug Cravings
8. Cholesterol provides immunity against infection by certain parasites
9. John Hopkins CGHH program provides Global Health education
10. London Hospital Provides Specialized Care For Pregnant Women
11. Hope Lodges provides free stay to cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... December 09, 2016 , ... Even with breast cancer ... greatly in recent years. This can be attributed to the improvement in breast ... equally distributed. In response, Mediaplanet’s latest, cross-platform edition of “Breast Cancer Care” spotlights ...
(Date:12/10/2016)... ... December 10, 2016 , ... Denver-based humanitarian aid organization, ... war—babies and toddlers. , The situation in Syria continues to worsen—deadly weapon explosions ... and dying from disease. The situation is intensifying with winter coming and airstrikes ...
(Date:12/9/2016)... ... , ... Cellairis is a worldwide mobile device and computer repair franchise that ... and Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up ... accessibility for customers. While customers do their shopping, Cellairis can accomplish a number of ...
(Date:12/9/2016)... ... 09, 2016 , ... Sober College, the game-changing dual diagnosis ... of the Sober College Robert Pfeifer Memorial Learning Center at its location in ... attended by an overwhelming amount of alumni, family, colleagues and friends of Sober ...
(Date:12/9/2016)... ... 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated patient ... solution for Emergency Departments (ED) has been added to their portfolio. Housed in ... rooms, and with a simplified pallet of information available to the patient, the ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)...  Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... filed a lawsuit for patent infringement.  The lawsuit, filed ... of Delaware , alleges that Nevro ... stimulation leads, batteries, and telemetry units. ...
(Date:12/9/2016)... 2016 MSD, a nationally recognized supplier of ... alternate site health care facilities, announced today that it ... ("First Choice"), a privately held national distributor of medical ... home health segments. We would like to welcome First ... compelling transaction will deliver significant and immediate value to ...
(Date:12/9/2016)... , December 9, 2016 ... Subcutaneous ICD, Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization ... Defibrillators, Wearable Cardioverter Defibrillators The ... at a CAGR of 5.3% from 2016-2020 and ... expected to grow at a CAGR of 5.2% ...
Breaking Medicine Technology: